This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Site Enhances New Modality CRDMO Platform Capacity for Customers
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
